OH-PROCTER-&-GAMBLE
5.1.2022 17:07:11 CET | Business Wire | Press release
Today, P&G Beauty debuted their virtual storytelling world, BeautySPHERE, at the Consumer Electronics Show. A first step into the metaverse, BeautySPHERE allows visitors to virtually interact with P&G Beauty’s portfolio of brands through live and simulated content.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005173/en/
“BeautySPHERE was inspired by our ongoing commitment to find new and surprising ways for people to connect with our brands, products and values,” shares Alex Keith, CEO, P&G Beauty. “Our hope is that, through these fully immersive, digital experiences, visitors can interact with our brands in surprising, engaging new ways.”
BeautySPHERE, which can be accessed from any desktop, offers a journey of discovery through Responsible Beauty, P&G Beauty’s platform for being a positive force for beauty in the world. With engaging content, livestream panel discussions and a gamified challenge, visitors will learn about the interconnected Responsible Beauty principles of Sustainability, Safety, Transparency, Quality & Performance, and Equality, Inclusion & Wellbeing.
BeautySPHERE visitors will be guided through immersive video content sharing ways P&G Beauty has already brought the Responsible Beauty principles to life through its portfolio of brands. The content underscores Responsible Beauty’s commitment to help inspire others, advance progress, and speed positive change.
“Outside of BeautySPHERE, these principles drive real-world impact and serve as our blueprint of innovation and product development for generations to come,” said Alexis Schrimpf, Vice President of Design, Global Skin and Personal Care. “We’re excited to share this approach with more people around the world through BeautySPHERE.”
During CES, BeautySPHERE will host six Responsible Beauty livestream panels (Wednesday, January 5 through Friday, January 7), featuring discussions with P&G researchers, brand experts and innovators as well as metaverse expert Cathy Hackl, who advised P&G on the strategy for BeautySPHERE, and Twitch streamer Kelsey Impicciche. Each panel will offer an insightful discussion on topics connected to product safety, equality and inclusion and more. Visit BeautySPHERE.com for the full schedule.
BeautySPHERE participants can also virtually visit the world’s leader in plant science, the Royal Botanic Gardens, Kew, to learn how P&G scientists partner with Kew’s experts to verify that the botanicals used in Herbal Essences bio:renew products are legitimate and of high quality. As part of the experience, visitors can authenticate their own botanical ingredients, guided by best-selling author, philanthropist, and Pantene ambassador Katie Piper, who will educate visitors about the plants they discover. Piper champions her own Responsible Beauty principles of transparency and inclusion when raising awareness for fellow survivors of acid attacks. Her foundation aims to have a world where scars do not limit a person’s function, social inclusion or sense of well-being.
Schrimpf added, “In the spirit of Responsible Beauty, every BeautySPHERE participant who completes our virtual Herbal Essences journey will have the opportunity to make a positive impact in the real world by helping plant a real tree in Veracruz, Mexico a region that supports restoration of native forest ecosystems.”
The BeautySPHERE 3D interactive experience can be easily accessed from home or anywhere with a desktop computer at: BeautySPHERE.com . BeautySPHERE doesn’t end with CES but is the first step in offering education and engaging brand experiences. In the meantime, to learn more about P&G Responsible Beauty, please visit https://us.pg.com/responsible-beauty/ .
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .
About Royal Botanic Gardens, Kew
The Royal Botanic Gardens, Kew is a world-famous scientific organisation, internationally respected for its outstanding collections as well as its scientific expertise in plant diversity, conservation and sustainable development in the UK and around the world. Kew Gardens is a major international and a top London visitor attraction. Kew Gardens’ 132 hectares of landscaped gardens, and Wakehurst, Kew’s Wild Botanic Garden, attract over 2.5 million visits every year. Kew Gardens was made a UNESCO World Heritage Site in July 2003 and celebrated its 260th anniversary in 2019. Wakehurst is home to Kew's Millennium Seed Bank, the largest wild plant seed bank in the world. RBG Kew receives approximately one third of its funding from Government through the Department for the Environment, Food and Rural Affairs (Defra) and research councils. Further funding needed to support RBG Kew’s vital work comes from donors, membership and commercial activity including ticket sales.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005173/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom